@article{327,
  keywords = {China, Clofazimine, Dapsone, Drug Therapy, Combination, Follow-Up Studies, Humans, leprosy, Recurrence, Retrospective Studies, Rifampin, Risk Factors},
  author = {Li H Y},
  title = {Problems of leprosy relapse in China.},
  abstract = {<p>The proportion of relapses among all patients detected each year increased steadily since the initiation of the national leprosy control program in China with dapsone monotherapy in 1955, reaching 18%-24% in the more leprosy-endemic provinces along the coast. Relapses were also reported in the formerly rifampin-plus-dapsone-treated patients. So far, only three paucibacillary relapses after 6 months of multidrug therapy (MDT) have been reported, and these were due to misclassification at the time of diagnosis. A short course of MDT should be given to all formerly dapsone- and/or rifampin-plus-dapsone-cured patients for the prevention of relapse. If not, they should be screened every 1 to 2 years for any possible signs of relapse, and MDT given when needed.</p>},
  year = {1993},
  journal = {International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association},
  volume = {61},
  pages = {1-7},
  month = {1993 Mar},
  issn = {0148-916X},
  url = {http://ila.ilsl.br/pdfs/v61n1a01.pdf},
  language = {eng},
}